Lotte Bjerre Knudsen from Novo Nordisk is a new honorary professor at Health, Aarhus University. She is the person behind the discovery of liraglutide, a new class of drugs for Novo …

2019年2月27日 · Published in PharmaTimes magazine - March 2019. PharmaTimes talks to Lotte Bjerre Knudsen, inventor of diabetesdrug liraglutide and scientific vice president at Novo …

The GLP-1 class of medications for diabetes and obesity likely wouldn’t be the phenomenally successful story it is today if it weren’t for Lotte Bjerre Knudsen, the chief scientific adviser...

Lotte Bjerre Knudsen (født 10. marts 1964 [1]) er en dansk kemiingeniør og forsker der har været central hos Novo Nordisk i udviklingen af lægemidlerne med de aktive stoffer liraglutid og …

Lotte Bjerre Knudsen is a Danish national, born in 1964 in a small town near Copenhagen. She holds a degree in biotechnology from the Technical University of Denmark, and a Doctoral …

Glucagon-like peptide-1- (9-36) amide is a major metabolite of glucagon-like peptide-1- (7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the … K Madsen, LB...

2024年1月8日 · Knudsen: I don’t care that much about money, I’m a socialist! Here in Scandinavia, we teach our children teamwork from an early age. It’s not about the individual. …

2023年10月17日 · Lotte Bjerre Knudsen, a chief scientific adviser at Novo Nordisk whose passionate belief in harnessing GLP-1 biology was instrumental to the company's success in …

2024年4月4日 · For their role in ensuring glucagon-like peptide-1 (GLP-1) receptor agonist medications were developed beyond diabetes, the Mani L. Bhaumik Breakthrough of the Year …